Cargando…
Osteosarcoma in Children: Not Only Chemotherapy
Osteosarcoma (OS) is the most severe bone malignant tumor, responsible for altered osteoid deposition and with a high rate of metastasis. It is characterized by heterogeneity, chemoresistance and its interaction with bone microenvironment. The 5-year survival rate is about 67% for patients with loca...
Autores principales: | Argenziano, Maura, Tortora, Chiara, Pota, Elvira, Di Paola, Alessandra, Di Martino, Martina, Di Leva, Caterina, Di Pinto, Daniela, Rossi, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471047/ https://www.ncbi.nlm.nih.gov/pubmed/34577623 http://dx.doi.org/10.3390/ph14090923 |
Ejemplares similares
-
Can Denosumab be used in combination with Doxorubicin in Osteosarcoma?
por: Punzo, Francesca, et al.
Publicado: (2020) -
Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia
por: Argenziano, Maura, et al.
Publicado: (2021) -
Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells
por: Punzo, Francesca, et al.
Publicado: (2020) -
Biological Aspects of Inflamm-Aging in Childhood Cancer Survivors
por: Rossi, Francesca, et al.
Publicado: (2021) -
Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors
por: Rossi, Francesca, et al.
Publicado: (2022)